Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: Results through 1 year of the GO-ALIVE study

John D. Reveille, Atul Deodhar, Paul H. Caldron, Anna Dudek, Diane D. Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H. Leu, Elizabeth C. Hsia

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Objective. Evaluate safety and efficacy of intravenous (IV) golimumab (GOL) in patients with active ankylosing spondylitis (AS) through 1 year. Methods. A total of 208 patients were randomized to IV infusions of GOL 2 mg/kg (n = 105) at weeks 0, 4, and every 8 weeks thereafter or placebo (n = 103) at weeks 0, 4, and 12, then crossover to GOL at weeks 16, 20, and every 8 weeks thereafter through Week 52. Efficacy was assessed using the Assessment of Spondyloarthritis international Society (ASAS) criteria, the Ankylosing Spondylitis Disease Activity Score (ASDAS), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and the Bath Ankylosing Spondylitis Functional Index (BASFI). Health-related quality of life was assessed using the AS Quality of Life (ASQoL) index. Efficacy and safety were monitored through Week 52 and Week 60, respectively. Results. The primary endpoint (ASAS20) and all controlled endpoints at Week 16 were achieved. At Week 52, 69.5% and 65.0% of patients in the GOL group and placebo crossover group, respectively, achieved an ASAS20; 56.2% and 51.5% achieved an ASAS40; 56.2% and 55.3% achieved a BASDAI50; 24.8% and 24.3% achieved ASAS partial remission; and 25.7% and 26.2% met ASDAS inactive disease criteria (all last observation carried forward). Mean changes from baseline to Week 52 in BASFI and ASQoL scores were similar between the GOL group and the placebo crossover group (BASFI: –2.7 and –2.6; ASQoL: –5.5 and –5.4). Through Week 60, 55.4% of all GOL-treated patients had ≥ 1 adverse events (AE); 3.4% had ≥ 1 serious AE. Conclusion. Efficacy was maintained through 1 year with IV GOL 2 mg/kg among patients with active AS. AE were consistent with the known safety profile of GOL.

Original languageEnglish (US)
Pages (from-to)1277-1283
Number of pages7
JournalJournal of Rheumatology
Issue number10
StatePublished - 2019


  • Ankylosing spondylitis
  • Anti-tumor necrosis factor therapy
  • Biologics
  • Golimumab
  • Intravenous

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: Results through 1 year of the GO-ALIVE study'. Together they form a unique fingerprint.

Cite this